Three Drug Combinations Based on Bortezomib and Dexamethasone (VD) Backbone Improve Renal Function More Efficiently Than VD in Myeloma Patients with Severe Renal Impairment

被引：0
|
作者：
Dimopoulos, Meletios A. [1 ]
Roussou, Maria [1 ]
Terpos, Evangelos [1 ]
Psimenou, Erasmia [1 ]
Gavriatopoulou, Maria [1 ]
Eleutherakis-Papaiakovou, Evangelos [1 ]
Kalapanida, Despoina [1 ]
Bakogeorgos, Marios [1 ]
Mparmparoussi, Despoina [2 ]
Vassilakopoulos, Theodoros P. [3 ]
Gika, Dimitra [1 ]
Matsouka, Charis [2 ]
Boletis, Ioannis [1 ]
Konstantopoulos, Kostas [1 ]
Kastritis, Efstathios [1 ]
机构：
[1] Univ Athens, Sch Med, Athens 11528, Greece
[2] Alexandra Gen Hosp, Athens, Greece
[3] Univ Athens, Laikon Gen Hosp, Athens 11528, Greece
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 5 条
  • [1] Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study
    Dimopoulos, Meletios A.
    Siegel, David
    White, Darrell J.
    Boccia, Ralph V.
    Yang, Zhao
    Kimball, Amy S.
    Iskander, Karim Saad
    Mezzi, Khalid
    Ludwig, Heinz
    Niesvizky, Ruben
    [J]. BLOOD, 2017, 130
  • [2] High Cut-off Hemodialysis Combined with Bortezomib-Based Therapy in Multiple Myeloma Patients with Severe Renal Impairment
    Baertsch, Marc-A.
    Raab, Marc S.
    Beimler, Joerg
    Meissner, Julia
    Schmier, Johann
    Goldschmidt, Hartmut
    Hillengass, Jens
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E120 - E120
  • [3] Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
    Leypoldt, Lisa B.
    Gavriatopoulou, Maria
    Besemer, Britta
    Salwender, Hans
    Raab, Marc S.
    Nogai, Axel
    Khandanpour, Cyrus
    Runde, Volker
    Jauch, Anna
    Zago, Manola
    Martus, Peter
    Goldschmidt, Hartmut
    Bokemeyer, Carsten
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    [J]. CANCERS, 2023, 15 (18)
  • [4] A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment
    Terpos, Evangelos
    Kastritis, Efstathios
    Symeonidis, Argiris
    Pouli, Anastasia
    Delimpasi, Sosana
    Katodritou, Eirini
    Hatzimichael, Eleftheria
    Ntanasis-Stathopoulos, Ioannis
    Malandrakis, Panagiotis
    Fotiou, Despina
    Migkou, Magdalini
    Theodorakakou, Foteini
    Spiliopoulou, Vasiliki
    Syrigou, Rodanthi
    Eleutherakis-Papaiakovou, Evangelos
    Manousou, Kyriaki
    Gavriatopoulou, Maria
    Dimopoulos, Meletios A.
    [J]. BLOOD, 2023, 142
  • [5] Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment
    Zannetti, Beatrice Anna
    Zamagni, Elena
    Santostefano, Marisa
    De Sanctis, Lucia Barbara
    Tacchetti, Paola
    Mancini, Elena
    Pantani, Lucia
    Brioli, Annamaria
    Rizzo, Raffaella
    Mancuso, Katia
    Rocchi, Serena
    Pezzi, Annalisa
    Borsi, Enrica
    Terragna, Carolina
    Marzocchi, Giulia
    Santoro, Antonio
    Cavo, Michele
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) : 647 - 652
1